Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: The N-SAS BC 02 trial

Value in Health

Volumn 14, Issue 5, 2011, Pages 746-751

  Shiroiwa, Takeru ^a   Fukuda, Takashi ^b   Shimozuma, Kojiro ^a   Kuranami, Masaru ^c   Suemasu, Kimito ^d   Ohashi, Yasuo ^b   Watanabe, Toru ^e  

^a RITSUMEIKAN UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d Arche Clinic   (Japan)

^e Hamamatsu City Med Ctr Devmtl M   (Japan)

Author keywords

anthracycline; breast cancer; EuroQoL 5D; functional assessment of cancer therapy; health related quality of life; taxane; utility

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG DOSE REGIMEN; EURO QOL 5 DIMENSION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; LINEAR MODELS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052436883     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.01.007     Document Type: Article

References (21)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
2. Ministry of Health, Labour and Welfare Vital Statistics [in Japanese] 2009 Ministry of Health, Labour and Welfare Tokyo
3. K. Gelmon The taxoids: paclitaxel and docetaxel Lancet 344 1994 1267 1272 (Pubitemid 24334685)
4. E.K. Rowinsky, and R.C. Donehower Paclitaxel (taxol) N Engl J Med 332 1995 1004 1014
5. M. De Laurentiis, G. Cancello, and D. D'Agostino Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 2008 44 53
6. K. Shan, A.M. Lincoff, and J.B. Young Anthracycline-induced cardiotoxicity Ann Intern Med 125 1996 47 58
7. M. Gold, J. Siegel, L. Russell, and M. Weinstein Cost Effectiveness in Health and Medicine 1996 Oxford University Press New York
8. D.F. Cella, D.S. Tulsky, and G. Gray The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J Clin Oncol 11 1993 570 579 (Pubitemid 23071057)
9. H. Fumimoto, K. Kobayashi, and C.H. Chang Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese Qual Life Res 10 2001 701 709 (Pubitemid 34145321)
10. EuroQol - a new facility for the measurement of health-related quality of life The EuroQol Group Health Policy 16 1990 199 208
11. A. Tsuchiya, S. Ikeda, and N. Ikegami Estimating an EQ-5D population value set: the case of Japan Health Econ 11 2002 341 353 (Pubitemid 34578418)
12. K. Shimozuma, Y. Ohashi, and A. Takeuchi Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02 Support Care Cancer 17 2009 1483 1491
13. M.J. Brady, D.F. Cella, and F. Mo Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument J Clin Oncol 15 1997 974 986 (Pubitemid 27106280)
14. D. Cella, A. Peterman, S. Hudgens, K. Webster, and M.A. Socinski Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane) Cancer 98 2003 822 831 (Pubitemid 36959280)
15. G. Verbeke, and G. Molenberghs Linear Mixed Models for Longitudinal Data 2000 Springer New York
16. D. Harville Maximum likelihood approaches to variance component estimation and to related problems J Am Stat Assoc 320 1977 40
17. A.S. Pickard, C.T. Wilke, H.W. Lin, and A. Lloyd Health utilities using the EQ-5D in studies of cancer Pharmacoeconomics 25 2007 365 384 (Pubitemid 46744468)
18. T. Watanabe, M. Kuranami, and K. Inoue Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: results of N-SAS-BC02 trial J Clin Oncol 27 15s 2009 516
19. Y.B. Cheung, J. Thumboo, and F. Gao Mapping the English and Chinese versions of the functional assessment of cancer therapy-general to the EQ-5D utility index Value Health 12 2009 371 376
20. N. Luo, J. Johnson, and S.J. Coons Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments Med Care 48 2010 365 371
21. A.S. Pickard, M.P. Neary, and D. Cella Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer Health Qual Life Outcomes 5 2007 70